Filing Flows › Angiodynamics (ANGO) › Q2 FY26
Angiodynamics (ANGO) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Jan 6, 2026
Angiodynamics (ANGO) reported revenue of $79.4M for the second quarter fiscal 2026 (Q2 FY26), +9% from a year earlier and +5% from the quarter before. Operating margin was -7.7%, net loss $6.3M (8.0% of revenue).
Angiodynamics, Q2 FY26: revenue $79.4M (+9% year over year), operating margin -7.7%, net loss $6.3M, operating cash flow $4.7M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $79.4M | +5% | +9% |
| Operating profit | −$6.1M | — | — |
| Net earnings | −$6.3M | — | — |
| Operating cash flow | $4.7M | — | +88% |
| Free cash flow | $4.2M | — | +153% |
What changed
Revenue was $79.4M in Q2 FY26, up 9% year over year and up 5% from the previous quarter. Med Device was the largest line at 55% of revenue. Med Tech added $4.1M year over year (up 13%), 62% of the total change.
Gross margin was 56.4%, up 1.6 points from a year earlier. Operating costs exceeded revenue by $6.1M, an operating margin of -7.7%. Operating expenses fell 0% while revenue rose 9%. The fastest-growing cost line was Research & development (+21%). The quarter ended with a net loss of $6.3M, narrower than the previous quarter's $10.9M loss.
Operating cash flow was $4.7M (up 88% year over year). Non-cash charges added back $5.8M of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items added $2.3M. Capital expenditures of $422K left free cash flow of $4.2M.
Questions
What was Angiodynamics' revenue in the second quarter fiscal 2026?
Angiodynamics (ANGO) reported revenue of $79.4M for the second quarter fiscal 2026 (Q2 FY26), +9% from a year earlier and +5% from the quarter before.
Was Angiodynamics profitable in the second quarter fiscal 2026?
Operating loss was $6.1M (-7.7% of revenue) and net loss $6.3M.
Source: Angiodynamics 10-Q on SEC EDGAR.